To further dissect the detailed mechanisms how Sorafenib and ASC‐J9® impacted the p‐STAT3 level, we focused on several known upstream signals that might activate p‐STAT3, and results revealed that p‐Src and Jak2 were significantly increased after Sorafenib treatment, and the sorafenib‐ASC‐J9® combination could reverse the increased expression of p‐Src and Jak2 in the 3 HCC cell lines (Fig. 3e). Here, JAK2 is linked to hepatocellular carcinoma.